PUBLIC COMPANY

$CELCCelcuity Inc.

Minneapolis, MN, USupdated 3h ago

SEC EDGAR Yahoo Finance

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1pre_registration

pre_registration

gedatolisib

Human Epidermal Growth Factor Receptor 2 Negative Breast…

PI3-kinase class ISerine/threonine-protein kinase mTOR

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Celcuity Inc. jobs →

News

no news has mentioned this company yet

May 13, 2026

earnings

2mo ago

Celcuity Inc. earnings

Celcuity Inc.

→

Data sources

SEC EDGAR

last refreshed 23m ago

Found something off?

Active trials

phase2Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancerrecruitingn=54
phase3Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)active not recruitingn=701
phase3Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)recruitingn=674
—Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009available

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$CELC108.25+0.28%

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 31, 26SELLBuller Richard E· 2,325 sh @ $110.11−$256K↗
Mar 31, 26SELLBuller Richard E· 675 sh @ $110.83−$75K↗
Jan 27, 26SELLDalvey David· 20,000 sh @ $120.03−$2.40M↗

routine RSU / option mechanics (4)

Apr 9, 26giftNIGON RICHARD · 10,000 sh
Mar 31, 26option exerciseBuller Richard E · 3,000 sh
Mar 31, 26option exerciseBuller Richard E · 3,000 sh
Feb 11, 26grantROMP CHARLES R · 215 sh